Evidence map›Paper›PMID 41535699›Full record

ArticleScientific reports2026

Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country.

Kim Sui Wan, Halizah Mat Rifin, Muhammad Fadhli Mohd Yusoff, Wah Kheong Chan, Kishwen Kanna Yoga Ratnam, Shubash Shander Ganapathy, Hamizatul Akmal Abd Hamid, Masni Mohamad, Nurain Mohd Noor, Feisul Mustapha and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kim Sui WanInstitute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, 40170, Selangor, Malaysia. kimsui@moh.gov.my.
Halizah Mat RifinInstitute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, 40170, Selangor, Malaysia.
Muhammad Fadhli Mohd YusoffInstitute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, 40170, Selangor, Malaysia.
Wah Kheong ChanGastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, 506303, Malaysia.
Kishwen Kanna Yoga RatnamInstitute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, 40170, Selangor, Malaysia.
Shubash Shander GanapathyInstitute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, 40170, Selangor, Malaysia.
Hamizatul Akmal Abd HamidInstitute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, 40170, Selangor, Malaysia.
Masni MohamadDepartment of Medicine, Putrajaya Hospital, Ministry of Health Malaysia, Putrajaya, 62250, Malaysia.
Nurain Mohd NoorDepartment of Medicine, Putrajaya Hospital, Ministry of Health Malaysia, Putrajaya, 62250, Malaysia.
Feisul MustaphaDisease Control Division, Ministry of Health Malaysia, Federal Government Administration Centre, Putrajaya, 62590, Malaysia.
Noor Ani AhmadInstitute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Shah Alam, 40170, Selangor, Malaysia.

Funding

Kementerian Kesihatan Malaysia 91000050
6 · The paper itself

Abstract

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) at the general population level in Malaysia is not known. This research aimed to determine the MALFD prevalence and the associated factors among adults in the country. The study utilised a cross-sectional study design with a two-stage stratified random sampling method across all states and federal territories in Malaysia. The data collection period was between July and September 2023, which included face-to-face interviews, clinical examinations, and venepuncture. MAFLD was defined as having a fatty liver (Fatty Liver Index of 60 or more) and the fulfillment of one or more of the three conditions: obesity or overweight, two or more abnormal metabolic risks, or having diabetes. There were 1,011 participants, and the MALFD prevalence was 28.2% (95% confidence intervals of 24.6% to 32.1%). Males, those with abdominal obesity, higher diastolic blood pressure, gamma-glutamyl-transferase, alanine aminotransferase, glycosylated haemoglobin A1c, and triglycerides had higher odds of having MAFLD. The Chinese ethnicity had the lowest odds for the condition compared to the Malay ethnic group. In short, MAFLD is common and of public health interest in Malaysia. Multidisciplinary and collective actions are needed from health policymakers, public health personnel, and physicians to manage the MAFLD epidemic in the country.

Indexed as

Fatty LiverNon-alcoholic Fatty Liver DiseaseAdultAgedAsian PeopleCross-Sectional StudiesEthnicityFemaleHumansMalaysiaMaleMiddle AgedPrevalenceRisk Factors

Identifiers

PMID41535699
PMCPMC12804704

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.